ABSTRACT
BACKGROUND Point-of-care rapid tests to identify SARS-CoV-2 can be of great help because, in principle, they allow decisions to be made at the site of care for treatment, or for the separation of cohorts avoiding cross-infection, especially in emergency situations.
METHODS A cross sectional study in adults requesting care in Emergency Rooms (ER), or the outpatient clinics of referral hospitals for COVID-19, to define the diagnostic characteristics of a rapid antigen test for SARS-CoV-2 (the Abbott Panbio™) having as a gold standard the RT-PCR for SARS-CoV-2. Health personnel in a routine situation within an active pandemic in several cities of Mexico performed the tests.
RESULTS A total of 1,069 participants with a mean age of 47 years (SD 16 years), 47% with a self-reported comorbidity, and an overall prevalence of a positive RT-PCR test of 45%, were recruited from eight hospitals in Mexico. Overall sensitivity of the Panbio test was 54.4% (95%CI 51-57) with a positive likelihood ratio of 35.7, a negative likelihood ratio of 0.46 and a Receiver-Operating Characteristics curve area of 0.77.
Positivity for the rapid test depended strongly on an estimate of the viral load (Cycle threshold of RT-PCR, Ct), and the days of symptoms. With a Ct≤25, sensitivity of the rapid test was 0.82 (95%CI, 0.76-0.87). For patients during the first week of symptoms sensitivity was 69.6% (95%CI 66-73). On the other hand, specificity of the rapid test was above 97.8% in all groups.
CONCLUSIONS The Panbio™ rapid antigen test for SARS-CoV-2 has a good specificity, but due to low and heterogeneous sensitivity in real life, a negative test in a person with suggestive symptoms at a time of community transmission of SARS-CoV-2 requires confirmation with RT-PCR, and after the first week of symptoms, sensitivity decreases considerably.
Competing Interest Statement
The antigen test kits were donated by the WHO / PAHO, and the Mexican Health Secretariat purchased additional tests of the same type for the hospital care of the patients. Code C93-20. No other additional support was available, and the expenses incurred were covered by the participating hospitals. Care of patients with COVID-19 was complimentary in all participating hospitals.
Clinical Trial
NCT04894760
Funding Statement
The antigen test kits were donated by the WHO / PAHO, and the Mexican Health Secretariat purchased additional tests of the same type for the hospital care of the patients. No other additional support was available, and the expenses incurred were covered by the participating hospitals. Care of patients with COVID-19 was complimentary in all participating hospitals.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was revised and approved (approval code C93-20) by El Comite Unico, de Investigacion, de Etica en Investigacion, y de Bioseguridad de la Comision Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad: The Investigation, Ethics in investigation and Biosecurity Unique Committee from the Coordination of the National Institutes of Health and High Specialty Hospitals, a single Institutional Review Board appointed by the NIH authority for this multicentric study. All hospitals that were included in the protocol belong to the same organisation and share the same administrative coordination and adhered to the same protocol and consent form, adding only the principal investigator of the participating institution. The trial was registered with ClinicalTrials.gov NCT04894760.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and Code Availability The data and codes related to the findings of this study will be available from the corresponding author after publication, upon reasonable request, especially from investigators compiling studies to of COVID-19. The group formed by the principal investigators will analyze the quality of the proposal and the security offered for the data. The patient-level data, without individual identifiers, will be shared after approval of the submitted proposal.
